The antiviral drug Triazavirin is the first medicine in the azoloazine group and the pioneer of this class of drugs. It was created in the bowels of Soviet military medicine. It took scientists about 30 years to develop Triazavirin. The drug is an innovation that was created in collaboration with the Institute of Military Medicine and the Institute of Influenza of St. Petersburg, then other organizations joined: the Virology Center of the Ministry of Defense of Russia, the Ural Federal University, etc. A large group of people including chemists, biologists, physicians, technologists, economists, and other specialists, took part in the creation of this drug.
In 2014, Triazavirin was registered and has since been used as a treatment of influenza. It is effective against over 15 strains of influenza and fevers, including swine and avian ones. Buy Triazavirin to fight a number of dangerous pathogenic viruses like Dengue and West Nile fever, tick-borne encephalitis, and other dangerous infections. Recently, they started using Triazavirin in case of exacerbations of bronchial asthma caused by viral infections.
In 2017, Triazavirin was included in the Federal Clinical Recommendations of the Ministry of Health of Russia as one of the four antiviral drugs with a direct antiviral effect. It has low toxicity, which is confirmed by many years of practice.
Chemically, it is a synthetic analog of guanine – an integral part of DNA with the help of which hereditary information is recorded. The instructions say that the drug inhibits the synthesis of the RNA virus and the replication of fragments of its genome. Simply put, it does not allow the virus to produce its copies in the affected cell. The drug is not aimed at eliminating the symptoms but acts directly on the contagious matron of the infection.
According to the results of clinical trials, Triazavirin can help even in case of a delayed start of the treatment of ARVI and influenza. It improves the general condition during the first days of the treatment, reduces the likelihood of complications; quickly inhibits clinical signs of rotavirus infection, and may prevent the worsening of the disease. It can reduce the time to recover and the duration of clinical symptoms (intoxication, fever, catarrhal phenomena), regardless of the treatment initiation. According to Dr. Chupakhin, PhD in Chemistry and Academician of the Russian Academy of Sciences, the virus is not spotted in the blood as soon as on the second day of the treatment with Triazavirin.
In 2016, this antiviral drug received a prestigious international pharmaceutical award the Prix Galien in the nomination “The Best Research in Russia”.
- Outpatient treatment of mild and moderate uncomplicated forms of influenza;
- Inpatient treatment of severe/complicated forms of influenza.
Produced by Medsintez Plant, Russia.
Dosage and administration
Method of application: per os, regardless of meals.
One 250 mg capsule 3 times a day, during 5–7 days. The daily dose is 750 mg.
The treatment with Triazavirin is well tolerated by patients and is rarely accompanied by the development of adverse reactions. It is important that the drug does not cause cardiovascular complications and does not interact with other agents.
Medsintez Plant, Russia.
- Karpenko I et al (2010). Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication. https://www.ncbi.nlm.nih.gov/pubmed/20194696
- Borisevich SV et al (2011). Therapeutic efficacy of Triazavirin, a novel Russian chemotherapeutic, against influenza virus A (H5N1). https://www.ncbi.nlm.nih.gov/pubmed/21780665
- Kiselev OI et al (2012). A new antiviral drug Triazavirin: results of phase II clinical trial. https://www.ncbi.nlm.nih.gov/pubmed/23477247
- Loginova SIa et al (2012). Toxicity of triazavirin, a novel Russian antiinfluenza chemotherapeutic. https://www.ncbi.nlm.nih.gov/pubmed/23700930
- Shvetsov AV et al (2018). Triazavirine supramolecular complexes as modifiers of the peptide oligomeric structure. https://www.ncbi.nlm.nih.gov/pubmed/28828928
$20.00 – $42.00
Vetom® is the brand name of the unique probiotic products manufactured by the Issledovatelsky Tsentr Research Company. They come in several forms: creams, sprays and capsules. They are intended for different applications. The main effect is immune system reinforcement. Bacteries of genus Bacillus are used as an active ingredient of Vetom medicinical products. These bacteria have an ability to suppress growth and development of pathogenic, conditionally pathogenic and putrefactive bacteria.
$35.00 – $40.00
Isoprinosine® is a synthetic antiviral compound formed from purine. The effectiveness of Isoprinosine is achieved by inhibition of RNA in the nucleus of a bacterial microorganism. The drug is known to block enzyme bonds, inhibiting the synthesis of the virus. Today it is used in Europe and elsewhere as a treatment against a number of viral diseases including herpes, influenza, and viral hepatitis. Fast US domestic shipping is available.
Cerebrum compositum® is a multi-component homeopathic medicine intended to improve brain metabolism. It's used in complex therapy of encephalopathy because it stimulates the immunity and cell regeneration. Cerebrum compositum helps enhance brain function and improve the overall body tone, performance and mood. It's built up of more than 20 homeopathic animal, herbal and mineral components.
Apilak® is a honey bee secretion from the glands in the hypopharynx of nurse bees. It contains a wide range of important vitamins (C, B1, B2, B5, B6, B8, B12, H, folate and inositol), minerals (K, Na, Ca, Mg, Fe and P), trace elements (Zn, Mn, Cu, Co, S, Si, Ni, Cr, As and Bi) and amino acids. Apilak activates the immune system in the recovery after illnesses, improves metabolism and the function of nervous and endocrine systems.